{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["tiragolumab","atezolizumab"]],"indication":"localized anal canal squamous cell carcinoma","name":"TIRANUS","nct_id":"NCT05661188","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tiranus-nct05661188. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TIRANUS","arms":[{"description":"TIRANUS is a Phase II, single-arm, open-label, non-randomized, multicenter clinical trial of atezolizumab and tiragolumab in concomitance with standard chemoradiotherapy as first-line in treatment-naïve, localized squamous cell carcinoma of the anal canal who are candidates for radical chemoradiotherapy. Patients with well differentiated stage I anal margin cancer or previously treated with immunotherapy are not eligible.\n\nAll patients receive atezolizumab (1200mg) plus tiragolumab (600 mg) for 2 cycles (Q3W) in concomitance with the 6 weeks of standard scheduled chemoradiotherapy (cisplatin: 60 mg/m² on days 1 and 29; 5-FU: 1000 mg/m² per day on days 1-4 and 29-32; radiotherapy: 1.8 Gy per day / total dose 54 Gy). After the concomitant phase, patients receive atezolizumab and tiragolumab for 6 additional cycles (consolidation phase).","label":"atezolizumab and tiragolumab in concomitancy with standard chemoradiotherapy","type":"EXPERIMENTAL"}],"collaborators":["Hoffmann-La Roche"],"completion_date":{"date":"2026-09-25","type":"ACTUAL"},"conditions":["Squamous Cell Carcinoma of the Anal Canal"],"enrollment":{"count":45,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Atezolizumab plus Tiraglolumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-07","lead_sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","official_title":"Phase II Study of Atezolizumab Plus Tiraglolumab in Combination With Chemoradiotherapy in Localized Squamous Cell Carcinoma of the Anal Canal","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-09-25","type":"ACTUAL"},"primary_outcomes":[{"measure":"Clinical complete response (CCR)","timeFrame":"End of consolidation phase (week 26)"},{"measure":"Clinical complete response (CCR) rate","timeFrame":"End of consolidation phase (week 26)"}],"references":[],"start_date":{"date":"2023-02-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)","url":"https://clinicaltrials.gov/study/NCT05661188"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tiranus-nct05661188"}